2024
Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial
Schindler E, Sewell R, Gottschalk C, Flynn L, Zhu Y, Pittman B, Cozzi N, D'Souza D. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. Journal Of The Neurological Sciences 2024, 460: 122993. PMID: 38581739, DOI: 10.1016/j.jns.2024.122993.Peer-Reviewed Original ResearchConceptsAttack frequencyCluster headacheCluster headache attack frequencyExtension phaseEffects of repeated treatmentReduction of attack frequencyPlacebo-controlled studyHeadache attack frequencyAdministration of psilocybinRandomized controlled trialsDouble-blindPsilocybin administrationPulse regimenAdverse eventsPulse regimensHeadache diaryTherapeutic efficacyDrug sessionsPulse administrationHeadacheStudy participantsWeeks
2023
Calcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder
Wang K, Fenton B, Deng Y, Anthony S, Dao V, Schindler E, Lipton R, Guirguis A, Skanderson M, Seng E, Sico J. Calcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder. JAMA Network Open 2023, 6: e2326371. PMID: 37523183, PMCID: PMC10391301, DOI: 10.1001/jamanetworkopen.2023.26371.Peer-Reviewed Original ResearchConceptsCalcitonin gene-related peptideSARS-CoV-2 infectionSevere COVID-19 outcomesCGRP mAbsMechanical ventilationSupplemental oxygenCOVID-19 outcomesSARS-CoV-2Cohort studyCGRP antagonistMAIN OUTCOMEMigraine disordersPositive SARS-CoV-2 test resultSARS-CoV-2 test resultsCOVID-19Protocol hazard ratiosRetrospective cohort studyMonoclonal antibody treatmentGene-related peptideLikelihood of hospitalizationCourse of diseasePeptide monoclonal antibodyElectronic health recordsNeuroimmune modulatorCumulative incidence
2020
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza D. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2020, 18: 534-543. PMID: 33184743, PMCID: PMC8116458, DOI: 10.1007/s13311-020-00962-y.Peer-Reviewed Original ResearchConceptsTherapeutic effectAdverse eventsSingle administrationPsychotropic effectsWeekly migraine daysSerious adverse eventsCross-over studyEffects of psilocybinOral placeboMigraine daysMigraine frequencyClinical effectsControlled StudyHeadache disordersMigraine headacheHeadache diaryDrug effectsDrug AdministrationNeuropsychiatric conditionsMigraineFinal analysisStudy proceduresReceptor ligandsWeeksAdministrationIn an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers
Schindler EAD, Schnakenberg Martin AM, Sewell RA, Ranganathan M, DeForest A, Pittman BP, Perrino A, D’Souza D. In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers. Psychopharmacology 2020, 237: 3097-3107. PMID: 32632491, DOI: 10.1007/s00213-020-05595-9.Peer-Reviewed Original ResearchConceptsCapsaicin-induced hyperalgesiaCross-over studyHealthy human subjectsIntravenous THCAcute painAntinociceptive effectDrug effectsDrug AdministrationHuman subjectsDose-related mannerPeak drug effectHealthy human volunteersSignificant antinociceptive propertiesRationaleAnimal studiesElectrical painPain conditionsPain managementChemical painPain ratingsAntinociceptive propertiesHealthy volunteersPsychoactive dosesAcute chemicalHuman studiesCognitive alterations
2018
Survey Analysis of the Use, Effectiveness, and Patient‐Reported Tolerability of Inhaled Oxygen Compared With Injectable Sumatriptan for the Acute Treatment of Cluster Headache
Schindler EAD, Wright DA, Weil MJ, Gottschalk CH, Pittman BP, Sico JJ. Survey Analysis of the Use, Effectiveness, and Patient‐Reported Tolerability of Inhaled Oxygen Compared With Injectable Sumatriptan for the Acute Treatment of Cluster Headache. Headache The Journal Of Head And Face Pain 2018, 58: 1568-1578. PMID: 30221765, DOI: 10.1111/head.13405.Peer-Reviewed Original ResearchConceptsInjectable sumatriptanCluster headacheAcute treatmentMedication responseOxygen deliverySide effectsPatient-reported side effectsSecondary analysisTherapeutic response rateCigarette smoking historyOptimization of therapyOptimal oxygen deliveryPositive predictorSmoking historyOxygen therapyCigarette smokingHeadache clinicTherapeutic optionsPatient populationPharmacologic interventionsTriptan medicationsComparable efficacyDaily attacksMale genderTherapeutic response
2016
Neuropsychiatric Presentation of Wilson Disease in an Adolescent Male
Schindler EA, Guo XM, Schrag M, Ghoshal S, Schilsky ML, Beslow LA. Neuropsychiatric Presentation of Wilson Disease in an Adolescent Male. Neuropediatrics 2016, 47: 346-347. PMID: 27490186, DOI: 10.1055/s-0036-1586225.Peer-Reviewed Original ResearchAdenosine TriphosphatasesAdolescentAggressionAntidepressive AgentsAntipsychotic AgentsAripiprazoleBrainCation Transport ProteinsCitalopramCopper-transporting ATPasesDepressionDiplopiaDysarthriaEsophageal and Gastric VaricesHepatolenticular DegenerationHumansHypertension, PortalImpulsive BehaviorLiver CirrhosisMagnetic Resonance ImagingMaleMutationSuicidal Ideation
2015
Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey
Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. Journal Of Psychoactive Drugs 2015, 47: 372-381. PMID: 26595349, DOI: 10.1080/02791072.2015.1107664.Peer-Reviewed Original ResearchConceptsCluster headacheIndoleamine hallucinogensConventional medicationsChronic cluster headachePain syndromePreventative medicationsAlternative medicationsLysergic acid diethylamideHeadache clinicConventional therapyCluster periodHeadacheMedicationsFinal analysisAcid diethylamideHallucinogensFurther investigationMost responsesSignificant numberAdditional evidenceParticipantsRemissionPatientsSyndromeClinic
2013
Clonidine Abuse in a Methadone-Maintained, Clonazepam-Abusing Patient
Schindler EA, Tirado-Morales DJ, Kushon D. Clonidine Abuse in a Methadone-Maintained, Clonazepam-Abusing Patient. Journal Of Addiction Medicine 2013, 7: 218-219. PMID: 23519051, DOI: 10.1097/adm.0b013e31828ab8d4.Peer-Reviewed Original Research
2012
Phospholipase C mediates (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex
Schindler EA, Harvey JA, Aloyo VJ. Phospholipase C mediates (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex. Brain Research 2012, 1491: 98-108. PMID: 23123701, PMCID: PMC3559188, DOI: 10.1016/j.brainres.2012.10.057.Peer-Reviewed Original ResearchMeSH KeywordsAmphetaminesAnimalsBehavior, AnimalCerebral CortexEnzyme ActivationEnzyme InhibitorsEstrenesHallucinogensHead MovementsHydrolysisLysergic Acid DiethylamideMaleMicroinjectionsPhosphatidylinositolsPrefrontal CortexPyrrolidinonesRabbitsReceptor, Serotonin, 5-HT2ASerotonin AntagonistsSerotonin Receptor AgonistsSignal TransductionType C PhospholipasesConceptsMedial prefrontal cortexLysergic acid diethylamidePI hydrolysisReceptor antagonistPrefrontal cortexDimethoxy-4Acid diethylamidePhospholipase CDistinct pharmacological propertiesEffects of hallucinogensActivation of PLCTissue prismsSerotonergic receptorsReceptor mechanismsPhosphatidylinositol hydrolysisPharmacological propertiesIntracellular mechanismsPLC inhibitorPLC activationHead bobsTrien-17Receptor signalsHallucinogensNovel findingsAntagonist
2011
Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD)
Schindler EA, Dave KD, Smolock EM, Aloyo VJ, Harvey JA. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Pharmacology Biochemistry And Behavior 2011, 101: 69-76. PMID: 22197710, PMCID: PMC3272148, DOI: 10.1016/j.pbb.2011.12.002.Peer-Reviewed Original ResearchConceptsHead-bobbing behaviourLysergic acid diethylamideReceptor antagonistEx vivoDimethoxy-4Acute drug injectionAcid diethylamideChronic drug treatmentBehavioral pharmacologyMechanism of actionReceptor binding propertiesDrug injectionDrug treatmentAnimal modelsReceptor activationBehavioral effectsClinical literatureReceptorsAntagonist ligandsNaïve rabbitsPharmacologyHallucinogensAntagonistAminopropaneVivo